TELA Bio

18 articles with TELA Bio

• TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive Surgery

  4/18/2019

  Innovative product portfolio based on TELA Bio's proven technology platform advances the design of biologic-based materials for reconstructive surgery.

• TELA Bio® to Present at 18th Annual Needham Healthcare Conference

  4/8/2019

  TELA Bio®, Inc. announced that the company will present at the 18th Annual Needham Healthcare Conference to be held April 9-10, 2019 at the Westin Grand Central Hotel in New York City.

• TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffolds

  1/24/2019

  TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the first patient has been treated with OviTex RBSs in Europe.

• TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.

  1/10/2019

  1,000 cm(2) device now commercially available in the U.S. rounds out portfolio of surgical mesh for full range of complex surgical procedures

• Nora Brennan Joins TELA Bio® as Chief Financial Officer

  1/2/2019

  TELA Bio is a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds for soft tissue repair

• TELA Bio® Announces Publication of Case Series Evaluating OviTex® Reinforced BioScaffolds in Hiatal and Inguinal Hernia Repair

  9/11/2018

  Two papers report no hernia recurrences during postoperative period, highlight advantages in repair reinforcement and pain management.

• TELA Bio® Announces Initial Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair

  6/7/2018

  Early outcomes from post-market clinical study presented at Abdominal Wall Reconstruction Conference in Washington, DC.

• TELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe

  5/31/2018

  Distinct class of surgical implants for hernia procedures to launch in Europe

• TELA Bio Announces Series B Investment by Checkmate Capital

  4/16/2018

  Surgical reconstruction company looks to forge long-term relationship with strategic investment group.

• TELA Bio Announces Investment Agreement with ProMedica Innovations Venture Fund

  3/26/2018

  Affiliate of leading integrated delivery network to invest $1 million in TELA Bio to form a strategic partnership in research and education

• TELA Bio Announces Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction

  3/12/2018

  Data presented at Americas Hernia Society International Hernia Congress 2018 show low recurrence and complication rates.

• TELA Bio Announces Hiring of Greg Firestone as VP of Strategic Customer Relations

  10/30/2017

  TELA Bio today announced that Greg Firestone has joined the company as VP of strategic customer relations and will be responsible for developing collaborative relationships.

• TELABio Initiates BRAVO Study Of OviTex Reinforced BioScaffolds For Hernia Repair

  4/25/2017

• TELABio Announces Settlement Of Litigation With Lifecell

  11/21/2016

• TELABio Announces OviTex Reinforced BioScaffolds Implanted In 100 Hernia Repair Procedures

  11/1/2016

• TELABio Announces Commercial Launch Of OviTex Reinforced BioScaffolds For Ventral Hernia Repair And Abdominal Wall Reconstruction

  7/13/2016

• TELABio Release: Results From Studies Of OviTex Reinforced BioScaffolds Presented At Abdominal Wall Reconstruction Conference

  6/16/2016

• Startup TELABio Raises $45.3 Million

  10/15/2014